301015: Qingdao Baheal Medical INC. - Summary | Jitta

Qingdao Baheal Medical INC.

CHN:301015

Price
CN¥26.89
Loss Chance
49.2%
4.99JITTA SCORE
314.49%Over Jitta Line
Jitta Ranking
191 / 486
1,905 / 5,270
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (46)
Recent Business Performance (27)
Financial Strength (77)
Return to Shareholders (53)
Competitive Advantage (47)
Jitta Signs
Debt LevelLow Long Term Debt
Revenue and EarningRevenue decline from 2022-2025
Operating MarginDeclined
Recent Business PerformanceEarning decline 40.82% in the last year
SG&A to SalesIncreasing Every Year
Key Stats
Jitta Score
Jitta Line
4.99
314.49%
4.23
> 1,000%
Health Care Distributors
6.90
13.19%
5.19
44.72%
3.01
100.00%
COMPANY DESCRIPTION
Qingdao Baheal Medical INC. engages in the research and development, production, wholesale, and retail of pharmaceutical products in China, the United States, Hong Kong, and internationally. The company offers bone health drugs under the D-Cal brand name; digestive drugs under the Mite brand name; and liver disease drugs under the Fuzhenghuayu brand name. It also provides tumor and other severe drugs under the Utidelon, Gore Ning, Mai Ruibei, and Hai Ruisi brand names; diabetes drugs under the Naida, Feburic, and Naite brand names; and medical nutrition under the Nutrasumma brand name, as well as skincare under the Cactus brand name. In addition, the company offers ZAP-X, an AI radiosurgery robot for intracranial tumors and lesions; Cifu VAD, the fully magnetically levitated ventricular assist device; and AtriCure Bipolar Radiofrequency Ablation Isolator for the treatment of chronic atrial fibrillation. The company was incorporated in 2005 and is based in Qingdao, China. Qingdao Baheal Medical INC. is a subsidiary of Baiyang Pharmaceutical Group Co., Ltd.